deltatrials
Terminated PHASE3 INTERVENTIONAL 1-arm NCT04000009

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Sponsor: ACADIA Pharmaceuticals Inc.

Interventions Pimavanserin
Updated 20 times since 2019 Last updated: Mar 31, 2022 Started: Jun 6, 2019 Primary completion: Feb 22, 2021 Completion: Feb 22, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated for business reasons and not due to safety concerns.

A PHASE3 clinical study on Adjunctive Treatment of Major Depressive Disorder, this trial is terminated or withdrawn. The trial is conducted by ACADIA Pharmaceuticals Inc. and has accumulated 20 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2022 · 13 months · monthly snapshot~May 2022 – ~Jul 2024 · 26 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

20 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. May 2022 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Apr 2021 — May 2022 [monthly]

    Terminated PHASE3

    Status: Active Not RecruitingTerminated

Show 15 earlier versions
  1. Mar 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  2. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  6. May 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  7. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE3

  8. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  9. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  10. Dec 2019 — Feb 2020 [monthly]

    Recruiting PHASE3

  11. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  12. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  13. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  14. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  15. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

    First recorded

Jun 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ACADIA Pharmaceuticals Inc.
Data source: ACADIA Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .